Table 1.
In vitro susceptibility testing of 125 VVC clinical isolates of Candida species to four triazole antifungal agents (MIC: minimum inhibitory concentration range, geometric (G) mean, MIC50, and MIC90 values are expressed in µg/ml)
| Strains (no.) and Antifungal drugs | S | SDD | R | Range MICs (μg/ml) | MIC50 / MIC90 (μg/ml) | Mode | G mean |
|---|---|---|---|---|---|---|---|
| Candida albicans (n=85) | |||||||
| FLC | 80 | 2 | 3 | 0.125-32 | 0.25/0.5 | 0.25 | 0.36 |
| ITC | 77 | 4 | 4 | 0.016-8 | 0.063/0.125 | 0.063 | 0.05 |
| VRC | 81 | 3 | 1 | 0.016-1 | 0.016/0.016 | 0.016 | 0.01 |
| POS | 80 | 1 | 4 | 0.016-1 | 0.016/0.125 | 0.016 | 0.03 |
| Candida glabrata (n=24) | |||||||
| FLC | - | 24 | - | 2-32 | 4/16 | 4 | 5.82 |
| ITC | 4 | 14 | 6 | 0.25-4 | 1/4 | 1 | 1.09 |
| VRC | 24 | - | - | 0.031-0.5 | 0.063/0.25 | 0.063 | 0.09 |
| POS | 18 | 4 | 2 | 0.25-4 | 0.5/2 | 0.5 | 0.53 |
| Pichia kudriavzevii (n=8) | |||||||
| FLC | - | - | 8 | 16-64 | - | - | - |
| ITC | 3 | 2 | 3 | 0.25-1 | - | - | - |
| VRC | 8 | - | - | 0.125-0.25 | - | - | - |
| POS | 7 | 1 | - | 0.125-1 | - | - | - |
| Cyberlindnera fabianii (n=4) | |||||||
| FLC | 2 | 1 | 1 | 0.25-16 | - | - | - |
| ITC | 1 | - | 3 | 0.016-2 | - | - | - |
| VRC | 4 | - | - | 0.016-0.125 | - | - | - |
| POS | 1 | 2 | 1 | 0.031-1 | - | - | - |
| Kluyveromyces marxianus (n=2) | |||||||
| FLC | 1 | 1 | - | 0.5-4 | - | - | - |
| ITC | 1 | - | 1 | 0.25-2 | - | - | - |
| VRC | 2 | - | - | 0.016-0.063 | - | - | - |
| POS | 2 | - | - | 0.125-0.5 | - | - | - |
| Candida africana (n=1) | |||||||
| FLC | - | 1 | - | 4 | - | - | - |
| ITC | - | - | 1 | 2 | - | - | - |
| VRC | 1 | - | - | 0.125 | - | - | - |
| POS | - | - | 1 | 1 | - | - | - |
| Candida parapsilosis (n=1) | |||||||
| FLC | - | - | 1 | 8 | - | - | - |
| ITC | - | - | 1 | 1 | - | - | - |
| VRC | - | 1 | - | 0.5 | - | - | - |
| POS | - | - | 1 | 1 | - | - | - |
VRC: Voriconazole; FLC: Fluconazole; ITC: Itraconazole; POS: Posaconazole